JW (Cayman) Therapeutics Valuation
Is 2126 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2126 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2126 (HK$1.32) is trading below our estimate of fair value (HK$12.39)
Significantly Below Fair Value: 2126 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2126?
Key metric: As 2126 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 2126's PS Ratio? | |
|---|---|
| PS Ratio | 2.9x |
| Sales | CN¥172.93m |
| Market Cap | CN¥497.19m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.05x |
| Enterprise Value/EBITDA | -0.02x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2126's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.8x | ||
2142 HBM Holdings | 1.6x | n/a | HK$879.3m |
6998 Genor Biopharma Holdings | 46.9x | n/a | HK$728.3m |
690 Uni-Bio Science Group | 0.7x | n/a | HK$376.2m |
2257 Sirnaomics | 26.2x | 63.5% | HK$219.6m |
2126 JW (Cayman) Therapeutics | 2.9x | 44.8% | HK$534.0m |
Price-To-Sales vs Peers: 2126 is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (18.8x).
Price to Sales Ratio vs Industry
How does 2126's PS Ratio compare vs other companies in the HK Biotechs Industry?
| 14 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 11.2x | 29.3% | |
2126 JW (Cayman) Therapeutics | 2.9x | 44.8% | US$68.64m |
6826 Shanghai Haohai Biological Technology | 2.1x | 11.8% | US$1.80b |
1530 3SBio | 1.4x | 9.3% | US$1.68b |
| 14 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 11.2x | 42.6% | |
2126 JW (Cayman) Therapeutics | 2.9x | -1.8% | US$68.64m |
Price-To-Sales vs Industry: 2126 is good value based on its Price-To-Sales Ratio (2.9x) compared to the Hong Kong Biotechs industry average (11.2x).
Price to Sales Ratio vs Fair Ratio
What is 2126's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.9x |
| Fair PS Ratio | 4.8x |
Price-To-Sales vs Fair Ratio: 2126 is good value based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (4.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
China Shineway Pharmaceutical Group
HK$6.3b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.34
7D
0.7%
1Y
n/a
3SBio
HK$13.1b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.55
7D
-2.5%
1Y
-25.1%
United Laboratories International Holdings
HK$18.2b
An investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
3933
HK$10.02
7D
1.8%
1Y
26.7%